Review



multiplex immunoassay  (Randox)


Bioz Verified Symbol Randox is a verified supplier
Bioz Manufacturer Symbol Randox manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Randox multiplex immunoassay
    Multiplex Immunoassay, supplied by Randox, used in various techniques. Bioz Stars score: 95/100, based on 186 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/pm41901695-70-6-8?v=Randox
    Average 95 stars, based on 186 article reviews
    multiplex immunoassay - by Bioz Stars, 2026-07
    95/100 stars

    Images



    Similar Products

    95
    Randox multiplex immunoassay
    Multiplex Immunoassay, supplied by Randox, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/pm41901695-70-6-8?v=Randox
    Average 95 stars, based on 1 article reviews
    multiplex immunoassay - by Bioz Stars, 2026-07
    95/100 stars
      Buy from Supplier

    90
    LINCO human cytokine linco-plex multiplex bead array
    Human Cytokine Linco Plex Multiplex Bead Array, supplied by LINCO, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/nct06401837-17-19-21?v=LINCO
    Average 90 stars, based on 1 article reviews
    human cytokine linco-plex multiplex bead array - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher bead-based multiplex cytokine array cytokine/chemokine/ growth factor 45-plex human procartaplex panel1
    Bead Based Multiplex Cytokine Array Cytokine/Chemokine/ Growth Factor 45 Plex Human Procartaplex Panel1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/pm40074901-585-1-12?v=Thermo+Fisher
    Average 90 stars, based on 1 article reviews
    bead-based multiplex cytokine array cytokine/chemokine/ growth factor 45-plex human procartaplex panel1 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Thermo Fisher bead-based multiplex cytokine array cytokine/chemokine/growth factor 45-plex human procartaplex panel1
    a-f , <t>Cytokine,</t> chemokine and growth factor profiles of serum from MIS-C patients during the first seven days of hospitalization ( n = 22), untreated samples are marked in red, and at follow-up visits ( n = 28 time points, 23 patients), paediatric patients during an acute infection with a asymptomatic to mild SARS-CoV-2 (mild; n = 57 of which n = 13 had no symptoms) or a moderate to severe (mod.; n = 42 of which teo had severe symptoms), of non-infected children ( n = 40 of which five have an underlying rheumatic condition) and of children six weeks after SARS-CoV-2-infection, that did not develop MIS-C ( n = 11 of which n = 5 have an underlying rheumatic condition). a , Type 1 cytokines, b , type 2 cytokines, c , type 3 cytokines, d , IL-1 family cytokines and e , chemokines and f , growth factors. g , Correlation of cytokine quantity versus time after hospitalization and initiation of treatment. h , Serum levels over time (0 indicates day of initiation of treatment) in individuals with MIS-C are indicated and decline in TGFβ1 serum levels was correlated to time after initiation of treatment. i-j , Graph view results of simple western size-based assay results for i , SMAD2/3 and j , phospho-SMAD2/3 (Ser465/467) (Fig. ) of primary T cells restimulated ex vivo with sera from indicated patients for 30 min with or without addition of a neutralizing anti-TGFβ prior to stimulation. k-m , HEK293T cells were transfected with a plasmid expressing a dominant negative mutant human TGFBR2 or a non-expressing plasmid with Blasticidin-resistance. After positive selection with Blasticidin, cells were stimulated with MIS-C patients’ sera (MIS-C; n = 4; yellow indicates sampling after start of treatment as indicated in i ) for 30 min or left unstimulated, lysed and SMAD2/3 and phospho-SMAD2/3 (Ser465/467) levels were quantified by Simple Western Size-Based assay. k , Phospho-SMAD2/3 (Ser465/467) levels normalised to total SMAD2/3 levels. l-m , Graph view results of simple western size-based assay results for ( l ) SMAD2/3 and m phospho-SMAD2/3 (Ser465/467). n-o , Graph view results of Tubulin used as a loading control for ( n ) T cells and ( o ) transfected HEK293T cells. a-f , Lower limits of quantification are indicated by horizontal lines, short lines indicate medians. A non-parametric ANOVA (Kruskal-Wallis test) was used followed by a Dunn’s multiple comparison test with correction for multiple comparisons, g-h , a two-tailed spearman-correlation was used, or k , a two-tailed ratio paired t-test was used.
    Bead Based Multiplex Cytokine Array Cytokine/Chemokine/Growth Factor 45 Plex Human Procartaplex Panel1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/pmc12003184-244-1-11?v=Thermo+Fisher
    Average 90 stars, based on 1 article reviews
    bead-based multiplex cytokine array cytokine/chemokine/growth factor 45-plex human procartaplex panel1 - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    96
    R&D Systems multiplex cytokine array kit
    a-f , <t>Cytokine,</t> chemokine and growth factor profiles of serum from MIS-C patients during the first seven days of hospitalization ( n = 22), untreated samples are marked in red, and at follow-up visits ( n = 28 time points, 23 patients), paediatric patients during an acute infection with a asymptomatic to mild SARS-CoV-2 (mild; n = 57 of which n = 13 had no symptoms) or a moderate to severe (mod.; n = 42 of which teo had severe symptoms), of non-infected children ( n = 40 of which five have an underlying rheumatic condition) and of children six weeks after SARS-CoV-2-infection, that did not develop MIS-C ( n = 11 of which n = 5 have an underlying rheumatic condition). a , Type 1 cytokines, b , type 2 cytokines, c , type 3 cytokines, d , IL-1 family cytokines and e , chemokines and f , growth factors. g , Correlation of cytokine quantity versus time after hospitalization and initiation of treatment. h , Serum levels over time (0 indicates day of initiation of treatment) in individuals with MIS-C are indicated and decline in TGFβ1 serum levels was correlated to time after initiation of treatment. i-j , Graph view results of simple western size-based assay results for i , SMAD2/3 and j , phospho-SMAD2/3 (Ser465/467) (Fig. ) of primary T cells restimulated ex vivo with sera from indicated patients for 30 min with or without addition of a neutralizing anti-TGFβ prior to stimulation. k-m , HEK293T cells were transfected with a plasmid expressing a dominant negative mutant human TGFBR2 or a non-expressing plasmid with Blasticidin-resistance. After positive selection with Blasticidin, cells were stimulated with MIS-C patients’ sera (MIS-C; n = 4; yellow indicates sampling after start of treatment as indicated in i ) for 30 min or left unstimulated, lysed and SMAD2/3 and phospho-SMAD2/3 (Ser465/467) levels were quantified by Simple Western Size-Based assay. k , Phospho-SMAD2/3 (Ser465/467) levels normalised to total SMAD2/3 levels. l-m , Graph view results of simple western size-based assay results for ( l ) SMAD2/3 and m phospho-SMAD2/3 (Ser465/467). n-o , Graph view results of Tubulin used as a loading control for ( n ) T cells and ( o ) transfected HEK293T cells. a-f , Lower limits of quantification are indicated by horizontal lines, short lines indicate medians. A non-parametric ANOVA (Kruskal-Wallis test) was used followed by a Dunn’s multiple comparison test with correction for multiple comparisons, g-h , a two-tailed spearman-correlation was used, or k , a two-tailed ratio paired t-test was used.
    Multiplex Cytokine Array Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/pmc11885818-293-1-5?v=R%26D+Systems
    Average 96 stars, based on 1 article reviews
    multiplex cytokine array kit - by Bioz Stars, 2026-07
    96/100 stars
      Buy from Supplier

    90
    Millipore mouse cytokine/chemokine multiplex bead array
    a-f , <t>Cytokine,</t> chemokine and growth factor profiles of serum from MIS-C patients during the first seven days of hospitalization ( n = 22), untreated samples are marked in red, and at follow-up visits ( n = 28 time points, 23 patients), paediatric patients during an acute infection with a asymptomatic to mild SARS-CoV-2 (mild; n = 57 of which n = 13 had no symptoms) or a moderate to severe (mod.; n = 42 of which teo had severe symptoms), of non-infected children ( n = 40 of which five have an underlying rheumatic condition) and of children six weeks after SARS-CoV-2-infection, that did not develop MIS-C ( n = 11 of which n = 5 have an underlying rheumatic condition). a , Type 1 cytokines, b , type 2 cytokines, c , type 3 cytokines, d , IL-1 family cytokines and e , chemokines and f , growth factors. g , Correlation of cytokine quantity versus time after hospitalization and initiation of treatment. h , Serum levels over time (0 indicates day of initiation of treatment) in individuals with MIS-C are indicated and decline in TGFβ1 serum levels was correlated to time after initiation of treatment. i-j , Graph view results of simple western size-based assay results for i , SMAD2/3 and j , phospho-SMAD2/3 (Ser465/467) (Fig. ) of primary T cells restimulated ex vivo with sera from indicated patients for 30 min with or without addition of a neutralizing anti-TGFβ prior to stimulation. k-m , HEK293T cells were transfected with a plasmid expressing a dominant negative mutant human TGFBR2 or a non-expressing plasmid with Blasticidin-resistance. After positive selection with Blasticidin, cells were stimulated with MIS-C patients’ sera (MIS-C; n = 4; yellow indicates sampling after start of treatment as indicated in i ) for 30 min or left unstimulated, lysed and SMAD2/3 and phospho-SMAD2/3 (Ser465/467) levels were quantified by Simple Western Size-Based assay. k , Phospho-SMAD2/3 (Ser465/467) levels normalised to total SMAD2/3 levels. l-m , Graph view results of simple western size-based assay results for ( l ) SMAD2/3 and m phospho-SMAD2/3 (Ser465/467). n-o , Graph view results of Tubulin used as a loading control for ( n ) T cells and ( o ) transfected HEK293T cells. a-f , Lower limits of quantification are indicated by horizontal lines, short lines indicate medians. A non-parametric ANOVA (Kruskal-Wallis test) was used followed by a Dunn’s multiple comparison test with correction for multiple comparisons, g-h , a two-tailed spearman-correlation was used, or k , a two-tailed ratio paired t-test was used.
    Mouse Cytokine/Chemokine Multiplex Bead Array, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/pm39920161-474-14-19?v=Millipore
    Average 90 stars, based on 1 article reviews
    mouse cytokine/chemokine multiplex bead array - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Eve Technologies Corporation luminex multiplex ‘mouse cytokine proinflammatory focused 10-plex discovery assay® array (mdf10)
    a-f , <t>Cytokine,</t> chemokine and growth factor profiles of serum from MIS-C patients during the first seven days of hospitalization ( n = 22), untreated samples are marked in red, and at follow-up visits ( n = 28 time points, 23 patients), paediatric patients during an acute infection with a asymptomatic to mild SARS-CoV-2 (mild; n = 57 of which n = 13 had no symptoms) or a moderate to severe (mod.; n = 42 of which teo had severe symptoms), of non-infected children ( n = 40 of which five have an underlying rheumatic condition) and of children six weeks after SARS-CoV-2-infection, that did not develop MIS-C ( n = 11 of which n = 5 have an underlying rheumatic condition). a , Type 1 cytokines, b , type 2 cytokines, c , type 3 cytokines, d , IL-1 family cytokines and e , chemokines and f , growth factors. g , Correlation of cytokine quantity versus time after hospitalization and initiation of treatment. h , Serum levels over time (0 indicates day of initiation of treatment) in individuals with MIS-C are indicated and decline in TGFβ1 serum levels was correlated to time after initiation of treatment. i-j , Graph view results of simple western size-based assay results for i , SMAD2/3 and j , phospho-SMAD2/3 (Ser465/467) (Fig. ) of primary T cells restimulated ex vivo with sera from indicated patients for 30 min with or without addition of a neutralizing anti-TGFβ prior to stimulation. k-m , HEK293T cells were transfected with a plasmid expressing a dominant negative mutant human TGFBR2 or a non-expressing plasmid with Blasticidin-resistance. After positive selection with Blasticidin, cells were stimulated with MIS-C patients’ sera (MIS-C; n = 4; yellow indicates sampling after start of treatment as indicated in i ) for 30 min or left unstimulated, lysed and SMAD2/3 and phospho-SMAD2/3 (Ser465/467) levels were quantified by Simple Western Size-Based assay. k , Phospho-SMAD2/3 (Ser465/467) levels normalised to total SMAD2/3 levels. l-m , Graph view results of simple western size-based assay results for ( l ) SMAD2/3 and m phospho-SMAD2/3 (Ser465/467). n-o , Graph view results of Tubulin used as a loading control for ( n ) T cells and ( o ) transfected HEK293T cells. a-f , Lower limits of quantification are indicated by horizontal lines, short lines indicate medians. A non-parametric ANOVA (Kruskal-Wallis test) was used followed by a Dunn’s multiple comparison test with correction for multiple comparisons, g-h , a two-tailed spearman-correlation was used, or k , a two-tailed ratio paired t-test was used.
    Luminex Multiplex ‘Mouse Cytokine Proinflammatory Focused 10 Plex Discovery Assay® Array (Mdf10), supplied by Eve Technologies Corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/bio_rxiv__2024__09__27__615547-101-23-15?v=Eve+Technologies+Corporation
    Average 90 stars, based on 1 article reviews
    luminex multiplex ‘mouse cytokine proinflammatory focused 10-plex discovery assay® array (mdf10) - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    90
    Merck KGaA multiplex bead array 41-plex human cytokine/chemokine panel
    a-f , <t>Cytokine,</t> chemokine and growth factor profiles of serum from MIS-C patients during the first seven days of hospitalization ( n = 22), untreated samples are marked in red, and at follow-up visits ( n = 28 time points, 23 patients), paediatric patients during an acute infection with a asymptomatic to mild SARS-CoV-2 (mild; n = 57 of which n = 13 had no symptoms) or a moderate to severe (mod.; n = 42 of which teo had severe symptoms), of non-infected children ( n = 40 of which five have an underlying rheumatic condition) and of children six weeks after SARS-CoV-2-infection, that did not develop MIS-C ( n = 11 of which n = 5 have an underlying rheumatic condition). a , Type 1 cytokines, b , type 2 cytokines, c , type 3 cytokines, d , IL-1 family cytokines and e , chemokines and f , growth factors. g , Correlation of cytokine quantity versus time after hospitalization and initiation of treatment. h , Serum levels over time (0 indicates day of initiation of treatment) in individuals with MIS-C are indicated and decline in TGFβ1 serum levels was correlated to time after initiation of treatment. i-j , Graph view results of simple western size-based assay results for i , SMAD2/3 and j , phospho-SMAD2/3 (Ser465/467) (Fig. ) of primary T cells restimulated ex vivo with sera from indicated patients for 30 min with or without addition of a neutralizing anti-TGFβ prior to stimulation. k-m , HEK293T cells were transfected with a plasmid expressing a dominant negative mutant human TGFBR2 or a non-expressing plasmid with Blasticidin-resistance. After positive selection with Blasticidin, cells were stimulated with MIS-C patients’ sera (MIS-C; n = 4; yellow indicates sampling after start of treatment as indicated in i ) for 30 min or left unstimulated, lysed and SMAD2/3 and phospho-SMAD2/3 (Ser465/467) levels were quantified by Simple Western Size-Based assay. k , Phospho-SMAD2/3 (Ser465/467) levels normalised to total SMAD2/3 levels. l-m , Graph view results of simple western size-based assay results for ( l ) SMAD2/3 and m phospho-SMAD2/3 (Ser465/467). n-o , Graph view results of Tubulin used as a loading control for ( n ) T cells and ( o ) transfected HEK293T cells. a-f , Lower limits of quantification are indicated by horizontal lines, short lines indicate medians. A non-parametric ANOVA (Kruskal-Wallis test) was used followed by a Dunn’s multiple comparison test with correction for multiple comparisons, g-h , a two-tailed spearman-correlation was used, or k , a two-tailed ratio paired t-test was used.
    Multiplex Bead Array 41 Plex Human Cytokine/Chemokine Panel, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/multiplex+cytokine+array/pmc11395490-331-63-73?v=Merck+KGaA
    Average 90 stars, based on 1 article reviews
    multiplex bead array 41-plex human cytokine/chemokine panel - by Bioz Stars, 2026-07
    90/100 stars
      Buy from Supplier

    Image Search Results


    a-f , Cytokine, chemokine and growth factor profiles of serum from MIS-C patients during the first seven days of hospitalization ( n = 22), untreated samples are marked in red, and at follow-up visits ( n = 28 time points, 23 patients), paediatric patients during an acute infection with a asymptomatic to mild SARS-CoV-2 (mild; n = 57 of which n = 13 had no symptoms) or a moderate to severe (mod.; n = 42 of which teo had severe symptoms), of non-infected children ( n = 40 of which five have an underlying rheumatic condition) and of children six weeks after SARS-CoV-2-infection, that did not develop MIS-C ( n = 11 of which n = 5 have an underlying rheumatic condition). a , Type 1 cytokines, b , type 2 cytokines, c , type 3 cytokines, d , IL-1 family cytokines and e , chemokines and f , growth factors. g , Correlation of cytokine quantity versus time after hospitalization and initiation of treatment. h , Serum levels over time (0 indicates day of initiation of treatment) in individuals with MIS-C are indicated and decline in TGFβ1 serum levels was correlated to time after initiation of treatment. i-j , Graph view results of simple western size-based assay results for i , SMAD2/3 and j , phospho-SMAD2/3 (Ser465/467) (Fig. ) of primary T cells restimulated ex vivo with sera from indicated patients for 30 min with or without addition of a neutralizing anti-TGFβ prior to stimulation. k-m , HEK293T cells were transfected with a plasmid expressing a dominant negative mutant human TGFBR2 or a non-expressing plasmid with Blasticidin-resistance. After positive selection with Blasticidin, cells were stimulated with MIS-C patients’ sera (MIS-C; n = 4; yellow indicates sampling after start of treatment as indicated in i ) for 30 min or left unstimulated, lysed and SMAD2/3 and phospho-SMAD2/3 (Ser465/467) levels were quantified by Simple Western Size-Based assay. k , Phospho-SMAD2/3 (Ser465/467) levels normalised to total SMAD2/3 levels. l-m , Graph view results of simple western size-based assay results for ( l ) SMAD2/3 and m phospho-SMAD2/3 (Ser465/467). n-o , Graph view results of Tubulin used as a loading control for ( n ) T cells and ( o ) transfected HEK293T cells. a-f , Lower limits of quantification are indicated by horizontal lines, short lines indicate medians. A non-parametric ANOVA (Kruskal-Wallis test) was used followed by a Dunn’s multiple comparison test with correction for multiple comparisons, g-h , a two-tailed spearman-correlation was used, or k , a two-tailed ratio paired t-test was used.

    Journal: Nature

    Article Title: TGFβ links EBV to multisystem inflammatory syndrome in children

    doi: 10.1038/s41586-025-08697-6

    Figure Lengend Snippet: a-f , Cytokine, chemokine and growth factor profiles of serum from MIS-C patients during the first seven days of hospitalization ( n = 22), untreated samples are marked in red, and at follow-up visits ( n = 28 time points, 23 patients), paediatric patients during an acute infection with a asymptomatic to mild SARS-CoV-2 (mild; n = 57 of which n = 13 had no symptoms) or a moderate to severe (mod.; n = 42 of which teo had severe symptoms), of non-infected children ( n = 40 of which five have an underlying rheumatic condition) and of children six weeks after SARS-CoV-2-infection, that did not develop MIS-C ( n = 11 of which n = 5 have an underlying rheumatic condition). a , Type 1 cytokines, b , type 2 cytokines, c , type 3 cytokines, d , IL-1 family cytokines and e , chemokines and f , growth factors. g , Correlation of cytokine quantity versus time after hospitalization and initiation of treatment. h , Serum levels over time (0 indicates day of initiation of treatment) in individuals with MIS-C are indicated and decline in TGFβ1 serum levels was correlated to time after initiation of treatment. i-j , Graph view results of simple western size-based assay results for i , SMAD2/3 and j , phospho-SMAD2/3 (Ser465/467) (Fig. ) of primary T cells restimulated ex vivo with sera from indicated patients for 30 min with or without addition of a neutralizing anti-TGFβ prior to stimulation. k-m , HEK293T cells were transfected with a plasmid expressing a dominant negative mutant human TGFBR2 or a non-expressing plasmid with Blasticidin-resistance. After positive selection with Blasticidin, cells were stimulated with MIS-C patients’ sera (MIS-C; n = 4; yellow indicates sampling after start of treatment as indicated in i ) for 30 min or left unstimulated, lysed and SMAD2/3 and phospho-SMAD2/3 (Ser465/467) levels were quantified by Simple Western Size-Based assay. k , Phospho-SMAD2/3 (Ser465/467) levels normalised to total SMAD2/3 levels. l-m , Graph view results of simple western size-based assay results for ( l ) SMAD2/3 and m phospho-SMAD2/3 (Ser465/467). n-o , Graph view results of Tubulin used as a loading control for ( n ) T cells and ( o ) transfected HEK293T cells. a-f , Lower limits of quantification are indicated by horizontal lines, short lines indicate medians. A non-parametric ANOVA (Kruskal-Wallis test) was used followed by a Dunn’s multiple comparison test with correction for multiple comparisons, g-h , a two-tailed spearman-correlation was used, or k , a two-tailed ratio paired t-test was used.

    Article Snippet: A bead-based multiplex cytokine array (Cytokine/Chemokine/Growth Factor 45-Plex Human ProcartaPlex Panel1, ThermoFisher Scientific) was used according to the manufacturer’s protocol.

    Techniques: Infection, Simple Western, Ex Vivo, Transfection, Plasmid Preparation, Expressing, Dominant Negative Mutation, Selection, Sampling, Control, Comparison, Two Tailed Test